Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM)

被引：0
|
作者：
Vu, Ravi [1 ]
Wang, Michael [2 ]
Orlowski, Robert [2 ]
Stewart, A. Keith [3 ]
Jagannath, Sundar [4 ]
Kukreti, Vishal [5 ]
Taylor, Jessica [6 ]
Fuhrman, Diana [6 ]
Cruickshank, Scott [6 ]
Schwartz, Richard [6 ]
Kunkel, Lori [6 ]
Siegel, David [7 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Mayo Clin, Scottsdale, AZ USA
[4] St Vincents Comp Canc Ctr, New York, NY USA
[5] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[6] Proteolix Inc, Clin Operat, San Francisco, CA USA
[7] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[8] MMRC, Norwalk, CT USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：320 / 320
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study
    Jennifer Brown
    Ruth Plummer
    Todd M. Bauer
    Stephen Anthony
    John Sarantopoulos
    Filip De Vos
    Mike White
    Marco Schupp
    Ying Ou
    Ulka Vaishampayan
    Experimental Hematology & Oncology, 6
  • [42] A phase II study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma (RRMM)
    Siegel, D. S.
    Martin, T.
    Wang, M.
    Vij, R.
    Jakubowiak, A. J.
    Lonial, S.
    Trudel, S.
    Kukreti, V.
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F. J.
    Somlo, G.
    Zonder, J.
    Song, K.
    Stewart, A. K.
    Stadtmauer, E.
    Kunkel, L.
    Wear, S. Sandra
    Wong, A.
    Orlowski, R. Z.
    Jagannath, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 7 - 7
  • [43] Updated results of a phase Ib/II study of carfilzomib (CFZ) in patients (pts) with relapsed malignancies
    Lee, P.
    Wong, A. F.
    Burris, H. A., III
    Papadopoulos, K.
    Sausville, E. A.
    Rosen, P. J.
    Mendelson, D. S.
    Infante, J. R.
    Patnaik, A.
    Gordon, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Everolimus (EVE) for relapsed/refractory classical Hodgkin lymphoma (cHL): Open-label, single-arm, phase II study.
    Johnston, Patrick B.
    Pinter-Brown, Lauren C.
    Rogerio, Jaqueline Willemann
    Warsi, Ghulam
    Chau, Quincy
    Ramchandren, Rod
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] An open-label, single-arm phase II study of everolimus (RAD001) in patients with relapsed/refractory classical Hodgkin lymphoma (HL)
    Johnston, P. B.
    Lewis, L. T.
    Rogerio, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] PRELIMINARY DATA OF THE ONGOING OPEN-LABEL, SINGLE-ARM PHASE II STUDY OF MP0250 IN COMBINATION WITH BORTEZOMIB plus DEXAMETHASONE IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
    Goldschmidt, H.
    Raab, M. S.
    Duerig, J.
    Szarejko, M.
    Jurczyszyn, A.
    Grzasko, N.
    Vacca, A.
    Bringhen, S.
    D'Agostino, M.
    Gamberi, B.
    Haunschild, J.
    Hermann, F.
    Fiedler, U.
    Dawson, K.
    Harstrick, A.
    Acosta, J.
    Schreder, M.
    Knop, S.
    HAEMATOLOGICA, 2018, 103 : 13 - 13
  • [47] Tucidinostat plus toripalimab in patients with unresectable or metastatic melanoma: An open-label, single-arm phase II study
    Mao, Lili
    Dai, Jie
    Bai, Xue
    Kong, Yan
    Sheng, Xinan
    Chi, Zhihong
    Cui, Chuanliang
    Lian, Bin
    Tang, Bixia
    Yan, Xieqiao
    Wang, Xuan
    Li, Siming
    Zhou, Li
    Wei, Xiaoting
    Li, Juan
    Li, Caili
    Duan, Rong
    Xu, Huayan
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients
    Tomita, Yoshihiko
    Tatsugami, Katsunori
    Nakaigawa, Noboru
    Osawa, Takahiro
    Oya, Mototsugu
    Kanayama, Hiroomi
    Kondoh, Chihiro Nakayama
    Sassa, Naoto
    Nishimura, Kazuo
    Nozawa, Masahiro
    Masumori, Naoya
    Miyoshi, Yasuhide
    Kuroda, Shingo
    Tanaka, Shingo
    Kimura, Akiko
    Tamada, Satoshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (11) : 952 - 959
  • [49] A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; Prelininary results.
    Richardson, P
    Jagannath, S
    Hussein, M
    Berenson, J
    Singhal, S
    Irwin, D
    Williams, SF
    Bensinger, W
    Badros, AZ
    Vescio, R
    Kenvin, L
    Yu, ZN
    Olesnyckyj, M
    Faleck, H
    Zeldis, J
    Knight, R
    Anderson, KC
    BLOOD, 2005, 106 (11) : 449A - 449A
  • [50] PX-171-006: PHASE IB MULTICENTER DOSE ESCALATION STUDY OF CARFILZOMIB (CFZ) PLUS LENALIDOMIDE (LEN) AND LOW DOSE DEXAMETHASONE (LODEX) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM) - PRELIMINARY RESULTS
    Wang, M.
    Gutierrez, A.
    Niesvizky, R.
    Bensinger, B.
    Vallone, M.
    Gutierrez, A. A.
    Kauffman, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 431 - 431
12345